2/4
04:27 pm
gkos
iVeena Delivery Systems Announces Strategic Leadership Promotions to Accelerate Growth and Scientific Innovation [Yahoo! Finance]
Low
Report
iVeena Delivery Systems Announces Strategic Leadership Promotions to Accelerate Growth and Scientific Innovation [Yahoo! Finance]
2/3
07:12 am
gkos
Glaukos (NYSE:GKOS) was upgraded by analysts at William Blair to a "strong-buy" rating.
Low
Report
Glaukos (NYSE:GKOS) was upgraded by analysts at William Blair to a "strong-buy" rating.
2/2
12:20 am
gkos
A Look At Glaukos (GKOS) Valuation After FDA Label Expansion For iDose TR [Yahoo! Finance]
Low
Report
A Look At Glaukos (GKOS) Valuation After FDA Label Expansion For iDose TR [Yahoo! Finance]
2/1
10:36 pm
gkos
Assessing Glaukos (GKOS) After Recent Share Price Rebound And DCF Upside Potential [Yahoo! Finance]
Low
Report
Assessing Glaukos (GKOS) After Recent Share Price Rebound And DCF Upside Potential [Yahoo! Finance]
2/1
07:51 pm
gkos
How Investors May Respond To Glaukos (GKOS) FDA-Backed Repeat Protocol For iDose TR Implant [Yahoo! Finance]
Low
Report
How Investors May Respond To Glaukos (GKOS) FDA-Backed Repeat Protocol For iDose TR Implant [Yahoo! Finance]
1/31
07:03 pm
gkos
Director Sells GKOS 15,000 Shares for $1.9 Million [Yahoo! Finance]
Low
Report
Director Sells GKOS 15,000 Shares for $1.9 Million [Yahoo! Finance]
1/29
10:32 am
gkos
Wells sees potential upside after Glaukos' iDose repeat dosing label approved [Yahoo! Finance]
Low
Report
Wells sees potential upside after Glaukos' iDose repeat dosing label approved [Yahoo! Finance]
1/28
12:50 pm
gkos
Glaukos (NYSE:GKOS) had its price target raised by analysts at BTIG Research from $123.00 to $131.00. They now have a "buy" rating on the stock.
Low
Report
Glaukos (NYSE:GKOS) had its price target raised by analysts at BTIG Research from $123.00 to $131.00. They now have a "buy" rating on the stock.
1/28
08:27 am
gkos
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR [Yahoo! Finance]
Low
Report
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR [Yahoo! Finance]
1/28
07:00 am
gkos
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
Medium
Report
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
1/23
08:06 am
gkos
What Makes Glaukos (GKOS) a Good Investment? [Yahoo! Finance]
Medium
Report
What Makes Glaukos (GKOS) a Good Investment? [Yahoo! Finance]
1/22
08:06 am
gkos
Glaukos (NYSE:GKOS) had its price target raised by analysts at Stifel Nicolaus from $115.00 to $160.00. They now have a "buy" rating on the stock.
Low
Report
Glaukos (NYSE:GKOS) had its price target raised by analysts at Stifel Nicolaus from $115.00 to $160.00. They now have a "buy" rating on the stock.
1/20
07:15 am
gkos
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17 [Yahoo! Finance]
Low
Report
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17 [Yahoo! Finance]
1/20
07:00 am
gkos
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
Medium
Report
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
1/20
02:16 am
gkos
Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations [Yahoo! Finance]
Low
Report
Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations [Yahoo! Finance]
1/14
10:02 am
gkos
Glaukos (NYSE:GKOS) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Glaukos (NYSE:GKOS) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/14
08:47 am
gkos
Glaukos falls on preliminary Q4 iDose sales [Seeking Alpha]
High
Report
Glaukos falls on preliminary Q4 iDose sales [Seeking Alpha]
1/14
08:04 am
gkos
Glaukos (NYSE:GKOS) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $125.00 price target on the stock.
Medium
Report
Glaukos (NYSE:GKOS) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $125.00 price target on the stock.
1/13
04:43 pm
gkos
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance [Yahoo! Finance]
Medium
Report
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance [Yahoo! Finance]
1/13
04:37 pm
gkos
Glaukos reports preliminary Q4 results [Seeking Alpha]
Medium
Report
Glaukos reports preliminary Q4 results [Seeking Alpha]
1/13
04:05 pm
gkos
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
Medium
Report
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
1/9
07:00 am
gkos
Glaukos (NYSE:GKOS) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Glaukos (NYSE:GKOS) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/3
09:01 am
gkos
Glaukos Corporation (NYSE:GKOS): Are Analysts Optimistic? [Yahoo! Finance]
Medium
Report
Glaukos Corporation (NYSE:GKOS): Are Analysts Optimistic? [Yahoo! Finance]
1/3
07:28 am
gkos
Glaukos price target raised to $145 from $115 at Stephens [Yahoo! Finance]
Medium
Report
Glaukos price target raised to $145 from $115 at Stephens [Yahoo! Finance]
1/2
08:04 am
gkos
Glaukos (NYSE:GKOS) had its "overweight" rating reaffirmed by analysts at Stephens.
Low
Report
Glaukos (NYSE:GKOS) had its "overweight" rating reaffirmed by analysts at Stephens.